Magellan Health (NASDAQ:MGLN) issued an update on its FY 2019 earnings guidance on Friday morning. The company provided EPS guidance of $3.70-4.69 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.50. The company issued revenue guidance of $7.2-7.5 billion, compared to the consensus revenue estimate of $7.11 billion.Magellan Health also updated its FY19 guidance to $3.70-4.69 EPS.

NASDAQ:MGLN opened at $57.63 on Friday. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of 9.79, a PEG ratio of 1.54 and a beta of 0.47. Magellan Health has a 12 month low of $51.88 and a 12 month high of $112.25. The company has a current ratio of 1.72, a quick ratio of 1.67 and a debt-to-equity ratio of 0.55.

Magellan Health (NASDAQ:MGLN) last released its quarterly earnings results on Wednesday, November 7th. The company reported $1.45 EPS for the quarter, beating the Zacks’ consensus estimate of $1.17 by $0.28. The firm had revenue of $1.85 billion for the quarter, compared to analyst estimates of $1.85 billion. Magellan Health had a net margin of 1.49% and a return on equity of 10.93%. The company’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.64 earnings per share. Research analysts predict that Magellan Health will post 3.61 earnings per share for the current fiscal year.

A number of equities analysts have commented on MGLN shares. TheStreet lowered shares of Magellan Health from a b- rating to a c+ rating in a research report on Friday, November 9th. ValuEngine upgraded shares of Magellan Health from a strong sell rating to a sell rating in a research report on Wednesday, November 28th. Zacks Investment Research lowered shares of Magellan Health from a hold rating to a sell rating in a research report on Saturday, October 13th. Leerink Swann lowered shares of Magellan Health from an outperform rating to a market perform rating and reduced their price target for the company from $90.00 to $70.00 in a research report on Tuesday, November 13th. Finally, BidaskClub lowered shares of Magellan Health from a strong-buy rating to a buy rating in a research report on Friday, August 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. Magellan Health currently has a consensus rating of Hold and a consensus price target of $83.33.

WARNING: This news story was published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/12/08/magellan-health-mgln-issues-fy-2019-earnings-guidance.html.

Magellan Health Company Profile

Magellan Health, Inc provides healthcare management services in the United States. It operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine for health plans, care organizations, and employers.

Featured Story: What Are Treasury Bonds?

Earnings History and Estimates for Magellan Health (NASDAQ:MGLN)

Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.